|   LifeSciVC

The Promise Of Precision Neuroscience And Launch Of Arkuda Therapeutics

By Bruce Booth, DPhil, Partner

Neuroscience has had a tough run of news lately. With Amgen deprioritizing neuro this year, Pfizer doing the same last year, and others like BMS, GSK, and AZ cutting back on CNS a few years earlier, it would seem dark times for neuroscience R&D. Add to that the recent unpredictable complexity around Biogen’s aducanumab, where hugely expensive Phase 3 trials are caught in the maelstrom between negative futility and positive analysis, and it might further question why anyone would want to work in the space.

Read more.


  |   In the News

Atlas, Novo-backed biotech reels in ex-Nimbus CEO Don Nicholson as exec chairman, hooks $50M to conquer anemia

Brian MacDonald’s original foray into treating iron dysregulation by injecting hepcidin, a small peptide hormone key for iron homeostasis, didn’t quite get off the ground. This time, the former GSK executive is taking a fresh approach — by regulating hepcidin expression within the body.

Read more.


  |   From the Trenches

Ode to Patients

Due to meetings in London on a Friday and in Dortmund on the following Monday, I spent the weekend in London.  As I walked the streets appreciating its history, I could not help but think of the history of medicine, as well.  Images of leeches and bloodletting in Tudor times came to mind.  Imagine being a patient back then.

This blog was written by Samantha Truex, CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   From the Trenches

Leave No Stone Unturned: A Pipeline Story

Building a leading gene therapy pipeline in under two years (and a lot of air miles): how to persevere and make the calls that matter.

Throughout a career in business development I’ve sat at every seat at the negotiating table, but I count my experience building AVROBIO’s leading lentiviral vector (LV) ex vivo gene therapy pipeline as perhaps my most satisfying and extraordinary time in biotech.

This blog was written by Deanna Petersen, CBO of AVROBIO (@dmp9818), as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   In the News

Atlas unveils RNA-editing Korro Bio helmed by Nessan Bermingham

Nearly two years ago, Nessan Bermingham, Ph.D., handed the reins of Intellia Therapeutics over to John Leonard, M.D., the R&D chief who had built the company alongside him. After a break, he landed at Atlas Venture, the VC firm that helped launch Intellia in 2014 and that is now debuting Korro Bio, Bermingham’s latest project.

Read more.